Michael S. Leapman, MD, MHS
Associate Professor of UrologyCards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center
Assistant Professor, Chronic Disease Epidemiology
Contact Info
Urology
PO Box 208058
New Haven, CT 06520-8058
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center
Assistant Professor, Chronic Disease Epidemiology
Contact Info
Urology
PO Box 208058
New Haven, CT 06520-8058
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center
Assistant Professor, Chronic Disease Epidemiology
Contact Info
Urology
PO Box 208058
New Haven, CT 06520-8058
United States
About
Titles
Associate Professor of Urology
Clinical Program Leader, Prostate & Urologic Cancers Program, Yale Cancer Center; Assistant Professor, Chronic Disease Epidemiology
Biography
Clinical interests: Prostate cancer: low-risk prostate cancer, active surveillance, nerve-sparing robotic prostatectomy, focal therapy, high-risk disease, pelvic lymph node dissection, imaging, risk stratification; molecular imaging; PSMA; focal therapy; bladder cancer: intravesical therapy, TURBT, radical cystectomy with urinary diversion, continent urinary diversion, neobladder, ileal conduit. Kidney cancer: laparoscopic radical nephrectomy, laparoscopic partial nephrectomy, robotic partial nephrectomy, open radical nephrectomy, open partial nephrectomy. Testicular cancer. Upper tract urothelial carcinoma: laparoscopic, open nephroureterectomy, ureterectomy Watch a video with Dr. Michael Leapman >>
Michael Leapman, MD was drawn to the field of urology for the opportunity to care for patients with urologic cancers. He aims, above all, to deliver the highest level of care possible with the utmost consideration and compassion for the impact that cancer places on patients, as well as their families, friends and communities.
Dr. Leapman graduated from Cornell University where he majored in Neurobiology and Behavior, and received his medical school degree from the University of Maryland in Baltimore. He completed his General Surgery and Urology training at the Mount Sinai Hospital in New York, NY. Subsequently, he completed a urologic oncology fellowship at the University of California San Francisco (UCSF) accredited by the Society of Urologic Oncology. He joined the faculty at the Yale University School of Medicine and Yale Cancer Center in 2016, specializing in urologic oncology with a joint appointment at the West Haven Veterans Affairs Medical Center.
Appointments
Urology
Associate Professor on TermPrimaryChronic Disease Epidemiology
Assistant ProfessorSecondary
Other Departments & Organizations
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- COPPER Center
- Janeway Society
- Prism Study
- Prostate & Urologic Cancers Program
- Robotic Surgery and Laparoscopy
- Urologic Oncology
- Urology
- Yale Cancer Center
- Yale Medicine
- Yale School of Public Health
Education & Training
- MHS
- Yale University (2022)
- Fellowship
- University of California San Francisco (2016)
- Residency
- Mount Sinai Medical Center (2014)
- Internship
- Mount Sinai Medical Center (2010)
- MD
- University of Maryland School of Medicine (2009)
- BA
- Cornell University (2005)
Research
Overview
Medical Research Interests
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Preston C. Sprenkle, MD
Cary Gross, MD
Patrick A. Kenney, MD
Xiaomei Ma, PhD
Michaela Dinan, PhD
Henry S. Park, MD, MPH
Prostatic Neoplasms
Urologic Neoplasms
Publications
2024
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020
Ajjawi I, Loeb S, Cooperberg M, Catalona W, Gross C, Ma X, Leapman M. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA 2024, 332 PMID: 39565605, PMCID: PMC11579888, DOI: 10.1001/jama.2024.20580.Peer-Reviewed Original ResearchAltmetricPathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy
Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, Sprenkle P, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39521675, DOI: 10.1016/j.urolonc.2024.10.018.Peer-Reviewed Original ResearchConceptsMRI-TRUSMRI-TRUS fusionImage-guided biopsyFusion biopsyGG upgradingTRUS biopsyBiopsy strategyBiopsy typeNo significant differencePathological concordanceBiopsy techniqueHigh-resolution micro-ultrasoundMRI-TRUS fusion biopsyMultivariate logistic-regression analysisMRI fusion biopsySystematic transrectal ultrasoundProstate cancer patientsSignificant differenceMicro-ultrasoundLogistic-regression analysisMultivariable-analysisPathological downgradingPathological upgradingRandomized controlled trialsProstate biopsyCounty-level racial disparities in prostate cancer specific mortality from 2005 to 2020
Washington S, Fakunle M, Wang L, Braun A, Leapman M, Cowan J, Cooperberg M. County-level racial disparities in prostate cancer specific mortality from 2005 to 2020. JNCI Cancer Spectrum 2024, pkae109. PMID: 39495143, DOI: 10.1093/jncics/pkae109.Peer-Reviewed Original ResearchAltmetricConceptsNon-Hispanic blacksRacial disparitiesCancer-specific mortalityCancer outcomesAssociated with lower mortality riskProstate cancer-specific mortalityProstate cancer outcomesNon-Hispanic white patientsLinear mixed models evaluated associationsPrimary care providersSpecific mortalityRadiation oncologist densityLower mortality riskYear of deathBlack-white differencesRace-based disparitiesMortality disparitiesProvider densityCare providersCounty-level dataHospital bedsMortality riskData of menProstate cancer specific mortality riskWhite patientsManagement strategies for radio-recurrent prostate cancer: a comprehensive review
Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2024, 0: 0-0. DOI: 10.21037/tcr-24-245.Peer-Reviewed Original ResearchFeasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients with Low-Risk Prostate Cancer in the Community Practice.
Gaylis F, Leapman M, Ellis S, Hu S, Cooperberg M, Loeb S, Chen R, Cohen E, Dato P, Aynehchi S, David R, Topp R, Santomauro B, Ginsburg K, Catalona W. Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients with Low-Risk Prostate Cancer in the Community Practice. Urology Practice 2024, 101097upj0000000000000745. PMID: 39453985, DOI: 10.1097/upj.0000000000000745.Peer-Reviewed Original ResearchInter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap?
Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, Sprenkle P, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024 PMID: 39438211, DOI: 10.1016/j.urolonc.2024.10.002.Peer-Reviewed Original ResearchConceptsClinically significant PCaPI-RADS scoreDetect clinically significant PCaReporting of prostate cancerInter-reader reliabilityProstate cancerPI-RADSDiagnostic accuracyReceiver operating characteristicInter-readerPresence of clinically significant PCaProstate Imaging Reporting & Data SystemDetect clinically significant diseasePI-RADS 3 lesionsTertiary academic care centerMRI fusion biopsyPI-RADS 3Significant PCaProstate cancer managementClinically significant diseaseInter-reader agreementSubgroup of lesionsAcademic care centerIntraclass correlationMpMRI interpretationMolecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review
Fazekas T, Pallauf M, Kufel J, Miszczyk M, Tsuboi I, Matsukawa A, Laukhtina E, Kardoust Parizi M, Mancon S, Cadenar A, Schulz R, Yanagisawa T, Baboudjian M, Szarvas T, Gandaglia G, Tilki D, Nyirády P, Rajwa P, Leapman M, Shariat S. Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. European Urology Oncology 2024 PMID: 39414421, DOI: 10.1016/j.euo.2024.09.017.Peer-Reviewed Original ResearchConceptsProstate Imaging ReportingProstate cancerMagnetic resonance imagingMRI-invisible lesionsPI-RADSMRI visibilityImaging ReportingAssociated with oncologic outcomesBiologically aggressive prostate cancerHighest Prostate Imaging ReportingMultiparametric magnetic resonance imagingProstate magnetic resonance imagingPI-RADS 4PI-RADS scoreResonance imagingData System scoreAggressive prostate cancerStage prostate cancerMolecular correlatesClinically aggressive cancerPrognostic gene panelsSystematic biopsyAssociated with featuresOncological outcomesSystemic biopsyLong-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseSociodemographic disparities in prostate cancer imaging
Sundaresan V, Lokeshwar S, Sutherland R, Sohoni N, Golos A, Ajjawi I, Leapman M. Sociodemographic disparities in prostate cancer imaging. Abdominal Radiology 2024, 1-9. PMID: 39325212, DOI: 10.1007/s00261-024-04603-2.Peer-Reviewed Original ResearchConceptsProstate cancer imagingProstate cancerProstate cancer diagnosisMonitoring of prostate cancerProstate multiparametric MRISociodemographic disparitiesProstate cancer treatmentEquitable cancer careBiochemical recurrenceFactors associated with disparitiesMultiparametric MRIActive surveillanceTreatment planningBlack patientsCancer outcomesTreatment workflowDiagnostic imagingCancer careDiagnosisRural settingsProstateImaging utilizationTreatmentPatientsCancer imagingDiagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy
Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.Peer-Reviewed Original ResearchAltmetricConceptsProstate Health IndexMRI-ultrasound fusion targeted biopsyClinically significant prostate cancerFusion targeted biopsyPI-RADS 1Gleason grade groupMagnetic resonance imagingPhi densityPI-RADSProstate specific-antigenProstate biopsyImproved detection of clinically significant prostate cancerDetection of clinically significant prostate cancerPHI testingProstate health index densityElevated prostate-specific antigenMRI-ultrasound fusionProstate Imaging ReportingSignificant prostate cancerProstate-specific antigenSelection of patientsDetection of PCaReceiver operating characteristic curveCombination of magnetic resonance imagingMultivariate logistic regression
Clinical Trials
Current Trials
SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
HIC ID2000031290RoleSub InvestigatorPrimary Completion Date10/31/2024Recruiting ParticipantsGenderMaleAge18+ yearsCustomized Ablation of the Prostate With the TULSA Procedure Against Radical Prostatectomy Treatment: a Randomized Controlled Trial for Localized Prostate Cancer (CAPTAIN)
HIC ID2000030487RoleSub InvestigatorPrimary Completion Date12/01/2023Recruiting Participants
Academic Achievements & Community Involvement
honor John N. Forrest Jr. Prize for Mentorship in Student Research
Yale School of Medicine AwardDetails05/19/2022United Stateshonor Best Poster
International AwardEuropean School of Oncology, Conference on Active SurveillanceDetails03/14/2016Italyhonor Merit Award
National AwardConquer Cancer Foundation of the American Society of Clinical OncologyDetails12/01/2015United Stateshonor First Place Essay, History Section
Regional AwardAmerican Urological Association Western SectionDetails08/24/2015United Stateshonor Outstanding Abstract Selected for Oral Presentation
Regional AwardUniversity of California San FranciscoDetails07/01/2015United States
Clinical Care
Overview
Michael S. Leapman, MD, who specializes in prostate, bladder, testicular and kidney cancers, loves his work as a urologic oncologist.
“Every day, I have the ability to make a difference in a patient's life,” says Dr. Leapman. “It's a tremendous honor and responsibility, and it's very rewarding.”
A member of Yale Cancer Center, he sees patients at Smilow Cancer Hospital and the West Haven Veteran’s Administration. An assistant professor of urology at Yale School of Medicine, he studies the best treatments for prostate cancer and how gene expression signatures can predict the aggressiveness of this cancer.
“Hearing the emotionally wrought words ‘it’s cancer’ is extremely difficult to navigate,” he says. “So that's one of the issues that we are sensitive to, and continue to strive to improve.”
The patient-physician bond is essential in helping patients with prostate cancer, for example, to choose which kind of treatment is best: surgery, radiation therapy or active surveillance, an ongoing monitoring of what can be a slow-progressing disease.
“It really is a very special relationship between a urologist and a patient. I have found that the team at Yale is 100 percent invested in the outcomes of our patients, and we stand out by seeking to understand their concerns, goals by being there for them every step of the way.”
Clinical Specialties
Fact Sheets
Urologic Cancers
Learn More on Yale MedicineHormonal Therapy for Cancer
Learn More on Yale MedicineProstate Cancer
Learn More on Yale MedicineTransitional Cell Cancer of the Renal Pelvis and Ureter
Learn More on Yale Medicine
Board Certifications
Urology
- Certification Organization
- AB of Urology
- Original Certification Date
- 2018
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
- November 22, 2024
More Patients Opting for Close Monitoring of Early-stage Prostate Cancer
- November 19, 2024
2nd Annual Yale Urology Bulldog Debates Recap
- October 30, 2024
Yale Urology Research [Q3: July-September 2024]
- October 14, 2024
Dr. Michael Leapman on Yale Cancer Answers: Surgical Options for Prostate Cancer
Get In Touch
Contacts
Urology
PO Box 208058
New Haven, CT 06520-8058
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.